Barclays sees a buying opportunity in this biotech stock

May 1, 2026 6:00 AM

Barclays has maintained an “overweight” rating on a U.S. small-cap biotechnology stock, setting a price target of $157, after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found